Tenax Therapeutics Announces Director and Officer Changes
Ticker: TENX · Form: 8-K · Filed: Dec 4, 2024 · CIK: 34956
| Field | Detail |
|---|---|
| Company | Tenax Therapeutics, INC. (TENX) |
| Form Type | 8-K |
| Filed Date | Dec 4, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $410 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, governance, officer-appointment
TL;DR
Tenax Therapeutics just swapped out some board members and execs, might be a strategy shake-up.
AI Summary
On December 2, 2024, Tenax Therapeutics, Inc. filed an 8-K report detailing the election of new directors and the appointment of new officers. The filing also includes information on compensatory arrangements for certain officers. The company, formerly known as Oxygen Biotherapeutics, Inc., is based in Chapel Hill, NC.
Why It Matters
Changes in a company's board of directors and executive officers can signal shifts in strategy, governance, or operational focus.
Risk Assessment
Risk Level: medium — Changes in leadership and executive compensation can indicate internal shifts that may impact future performance.
Key Players & Entities
- TENAX THERAPEUTICS, INC. (company) — Registrant
- Oxygen Biotherapeutics, Inc. (company) — Former company name
- December 2, 2024 (date) — Date of earliest event reported
FAQ
What specific roles were filled by the newly appointed officers?
The filing indicates the appointment of certain officers and compensatory arrangements, but does not specify the exact roles filled in this summary.
Who are the newly elected directors?
The filing mentions the election of directors but does not list their names in the provided text.
What is the effective date of these changes?
The earliest event reported is December 2, 2024.
What is the primary business of Tenax Therapeutics, Inc.?
Tenax Therapeutics, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Where is Tenax Therapeutics, Inc. headquartered?
The company is headquartered in Chapel Hill, NC.
Filing Stats: 976 words · 4 min read · ~3 pages · Grade level 10.7 · Accepted 2024-12-04 17:16:10
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share TENX The Nasdaq
- $410 — receive cash compensation at a rate of $410 per hour for Mr. McGauley's services, w
Filing Documents
- tenx_8k.htm (8-K) — 27KB
- 0001654954-24-015161.txt ( ) — 149KB
- tenx-20241202.xsd (EX-101.SCH) — 6KB
- tenx-20241202_lab.xml (EX-101.LAB) — 14KB
- tenx-20241202_cal.xml (EX-101.CAL) — 1KB
- tenx-20241202_pre.xml (EX-101.PRE) — 9KB
- tenx-20241202_def.xml (EX-101.DEF) — 2KB
- tenx_8k_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 10.1 Consulting Agreement dated October 14, 2021, by and between Tenax Therapeutics, Inc. and Danforth Advisors, LLC (certain confidential portions (as indicated therein) of this exhibit have been omitted) (incorporated by reference to Exhibit 10.20 to the Company's Form 10-K for the period ended December 31, 2021, filed with the SEC on March 29, 2022). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 4, 2024 Tenax Therapeutics, Inc. By: /s/ Christopher T. Giordano Christopher T. Giordano President and Chief Executive Officer 3